Found 45 results in Expert Content

Summary: Originally published in Inhalation magazine, this article discusses how nasal powder formulations represent a significant stride in drug delivery innovation. With drug developers and approvers evolving to address the unique considerations of nasal drug delivery, nasal powders offer a robust and adaptable platform in the pharmaceutical landscape.

Summary: In this article, Dr. Alan Watts, Director of Innovation & Partnerships for Orally Inhaled Products at Catalent, and Michael Tauber, Senior Director of Pharmaceutical Development at Acorda Therapeutics discuss the requirements and benefits of using spray-dried powders for inhalation, and how ARCUS can be used to successfully bring new inhaled therapies to market.

Summary: This article discusses how to successfully develop and manufacture spray-dried pulmonary and nasal powders and how a CDMO partner plays an integral role in the successful development and commercialization of inhalation products.

Summary: Download this fact sheet to learn more about our experience and expertise with nitrosamines testing.

In this webinar, experts discuss problems common to the development, testing and manufacturing of intranasal drug products, their potential causes, and possible consequences.

Summary: This article explores the key factors pharmaceutical companies should consider when selecting a CDMO and evaluating its multi-product facility capable of handling HPAPIs to de-risk their programs and bring their products to patients safely.

Summary: Discover how Catalent, a specialized CDMO, accelerates time to market for inhalation innovators with end-to-end solutions.

Summary: In this article, experts discuss how the intranasal route offers advantages like faster absorption and minimal product degradation, but also the complex issues to consider when designing a device that will ensure the efficacy of a particular formulation.

Summary: This article, originally published in Inhalation Magazine, discusses process & applications considerations for the spray drying of inhaled powders, considerations for formulating biologics as respirable powders and inhalation for non-respiratory indications.

Summary: In this article experts shared their insights on developing intranasal products and scaling them for commercial supply.